ArticleLupus science & medicine2021
SARS-CoV-2 vaccines in patients with SLE.
Article in Lupus science & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Vaccination in systemic lupus erythematosus.Human vaccines & immunotherapeutics · 2026Review
- Post-publication corrections of rheumatology articles: a comprehensive analysis.Advances in rheumatology (London, England) · 2026Article
- Markers of Antiviral Response in SLE Patients After Vaccination Against SARS-CoV-2.International journal of molecular sciences · 2025Article
- Disease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE.Nature immunology · 2025Article
- Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus.JCI insight · 2024Article
- Bibliometric analysis of scientific papers on adverse reactions to COVID-19 vaccines published between 2019 and 2023.Human vaccines & immunotherapeutics · 2023Article
- Bioinformatics analyses of gene expression profile to identify pathogenic mechanisms for COVID-19 infection and cutaneous lupus erythematosus.Frontiers in immunology · 2023Article
- Presentation of SLE after COVID vaccination in a pediatric patient.BMC rheumatology · 2022Article
- Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE).Clinical immunology communications · 2022Article
- Systemic Lupus Erythematosus Following COVID-19 Vaccination.European journal of rheumatology · 2022Article
- Systematic lupus erythematous patients following COVID-19 vaccination: Its flares up and precautions.Annals of medicine and surgery (2012) · 2022Article
- Article
- BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.Annals of the rheumatic diseases · 2022Article
- Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- New-Onset Systemic Lupus Erythematosus after mRNA SARS-CoV-2 Vaccination.Case reports in rheumatology · 2022Article
- First Presentation of Systemic Lupus Erythematosus in a 24-Year-Old Male following mRNA COVID-19 Vaccine.Case reports in rheumatology · 2022Article
- COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis.Rheumatology international · 2021Review
- The Use of COVID-19 Vaccines in Patients with SLE.Current rheumatology reports · 2021Review
- Transition of cutaneous into systemic lupus erythematosus following adenoviral vector-based SARS-CoV-2 vaccination.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine.Dermatologic therapy · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmune diseases and the evidence available in the literature that may help in the decision process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.